ESTRO 2024 - Abstract Book

S246

Brachytherapy - Gynaecology

ESTRO 2024

(5% vs 7%, p = 0.57), grade 2+ GI toxicity (11% vs 20%, p = 0.13), or grade 2+ vaginal toxicity (14% vs 17%, p = 0.48), respectively. The 3-year cumulative grade 2+ GU toxicity rate was significantly lower in the 24 Gy/3Fr group compared to the 28 Gy/4Fr group (9% vs 23%, respectively, p = 0.03).

Conclusion:

Cervical cancer patients treated with 24 Gy/3Fr had similar DFS, LF, GI and vaginal toxicity rates, and a trend towards lower grade 2+ GU toxicity rate compared to those treated with 28 Gy/4Fr. A less resource intensive brachytherapy fractionation schedule of 24 Gy/3Fr is a safe alternative to 28 Gy/4Fr for definitive treatment of cervical cancer.

Keywords: cervical cancer, brachytherapy fractionation

1065

Proffered Paper

Image-guided adaptive brachytherapy for vaginal recurrence of endometrial cancer